शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
AMBALALSABSEAmbalal Sarabhai Enterprises Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 21 May, 2026 · 19:55 IST

We hereby submit details for Annual General Meeting of the Company. Kindly take the same on your records.

Profit growth above 25%Exceptional itemRelated-party transactionsResults View source PDFExplain this filing

AMBALALSA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.4%Reaction day
₹32.81
prior close
₹33.60
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.3% vs market
Pharmaceuticals peers, median of 164sector-0.1%+1.5% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.2
10m
+2.7
15m
+2.1
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.4+0.1+1.3-0.1+1.5
Next day
-1.0+1.7-2.7+0.9-1.9
2d
+0.2+2.4-2.2+0.9-0.7
3d
+6.6+2.4+4.3+0.7+5.9
4d
+8.5+1.7+6.8+0.8+7.7
5d
+8.6+0.6+8.0+0.0+8.6
1w
+8.8+1.9+6.9-0.1+8.9
15d
+0.7+4.9-4.2+1.2-0.4
1m
-3.4+8.9-12.3+3.0-6.4
2m
-4.4+7.5-11.9+4.7-9.1
3m
+34.1+13.6+20.5+7.9+26.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ambalal Sarabhai Enterprises reported FY2025-26 consolidated revenue of Rs. 20,227 Lakhs, up 3.1% YoY from Rs. 19,619 Lakhs. Consolidated PAT surged to Rs. 1,780 Lakhs versus Rs. 493 Lakhs prior year—a 261% jump driven by higher segment profitability (Pharma Rs. 1,315 Lakhs, Electronics Rs. 1,026 Lakhs) and reduced exceptional items (Rs. 82 Lakhs vs Rs. 700 Lakhs). The Board approved inter-corporate loans to three subsidiaries (Asence Pharma, Synbiotics, Systronics India), reappointed three key executive directors (Kartikeya V. Sarabhai as Executive Chairman, Ms. Chaula M. Shastri as Whole-time Director, Mr. Mohal K. Sarabhai as Managing Director), and continued Mr. Govindprasad Namdeo as Independent Director beyond age 75. The 48th AGM is scheduled for July 30, 2026 via VC. Statutory auditors issued unqualified opinions on both standalone and consolidated results.

Likely market impact

Strong bottom-line recovery with PAT growth over 261% and positive operating cash flow of Rs. 1,340 Lakhs signals improved operational efficiency, though modest 3% revenue growth suggests underlying business expansion is gradual.